The Efficacy of Transcutaneous Auricular Vagus Nerve Stimulation in Individuals With Tiletamine Use Disorder (taVNS-Tiletami)
2026년 7월 1일 업데이트: Shanghai Mental Health Center
Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Patients With Tiletamine Use Disorder: A Randomized Double-Blind Sham-Controlled Trial
Participants diagnosed with tiletamine use disorder will be assigned to active or sham taVNS for 5 days.
Clinical outcomes ( e.g., behavioral paradigms measures and clinical scales ) and physiological markers (e.g., EEG and ECG) will be evaluated at baseline, post-treatment, and 3-month follow-ups to determine therapeutic efficacy and mechanisms of action.
연구 개요
상태
아직 모집하지 않음
상세 설명
Tiletamine use disorder has emerged as a significant public health concern characterized by persistent psychological craving and high relapse rates. This randomized, double-blind, sham-controlled clinical trial aims to evaluate whether transcutaneous auricular vagus nerve stimulation (taVNS) can reduce craving levels and improve other outcomes in individuals with tiletamine dependence. Multimodal assessments including electroencephalography (EEG), electrocardiography (ECG) , behavioral paradigms measures and clinical scales will be conducted before and after the treatment.
This study seeks to establish a non-invasive vagus nerve stimulation strategy for substance use disorders and explore the treatment mechanism.
연구 유형
중재적
등록 (추정된)
30
단계
- 해당 없음
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 연락처
- 이름: Jiang Du, M.D, Ph.D
- 전화번호: +8618017311220
- 이메일: dujiangdou@163.com
연구 장소
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, 중국, 200030
- Shanghai Mental Health Center
-
연락하다:
- Jiang Du, M.D, Ph.D
- 전화번호: +86 021 6490 6315
- 이메일: dujiangdou@163.com
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
- 성인
건강한 자원 봉사자를 받아들입니다
아니
설명
Inclusion Criteria:
- Age 18-60 years ≥6 years of education[7.1] DSM-5 diagnosis of substance use disorder related to tiletamine Tiletamine use ≥6 months and ≥1 time/week Ability to provide informed consent Willingness to complete follow-up assessments
Exclusion Criteria:
- Severe cognitive impairment History of epilepsy, brain injury, neurological disease or serious psychiatric disease Use of cognition-enhancing medications within 6 months Other psychoactive substance abuse within past 5 years (except nicotine) Metal implants in the head or severe skin sensitivity
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Active taVNS
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation Stimulation site: Left cymba conchae Frequency: 20 Hz Pulse width: 500 μs Intensity: 0.5-4 mA (perceptible but non-painful) Session duration: 40 minutes Frequency: 4 sessions/day Treatment course: 5 days (20 sessions)
|
The stimulation duration is 40 minutes per session, administered four times daily for 5 consecutive days (20 sessions in total).
|
|
가짜 비교기: Sham taVNS
Intervention: Sham Stimulation Site: Ipsilateral earlobe Same device appearance and parameters Minimal sensory stimulation without vagal activation Same treatment schedule as active group
|
Identical device appearance and parameters, with minimal sensory stimulation and no vagal activation.
The treatment schedule is identical to that of the active group.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change of depressive symptoms
기간: Baseline, immediately after the intervention,one month after the intervention
|
The PHQ-9, fully known as the Patient Health Questionnaire-9, is a self-report assessment tool developed based on the diagnostic criteria in the American Diagnostic and Statistical Manual of Mental Disorders for screening and evaluating the severity of depression.
The scale consists of nine items corresponding to the core symptoms of depression.
Respondents rate the frequency of symptoms experienced over the past two weeks on a scale of 0 to 3. The total score ranges from 0 to 27, with higher scores indicating potentially more severe depressive symptoms.
|
Baseline, immediately after the intervention,one month after the intervention
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change of stress symptoms
기간: Baseline, immediately after the intervention, one month after the intervention,
|
PSS stands for the Perceived Stress Scale.
It is used to assess an individual's subjective perceptions of stress and the frequency of stress-related thoughts and feelings over the past month.
The scale consists of 14 items, with derived 10-item and 4-item versions also available, and uses a five-point scoring system from 0 to 4, ranging from "never" to "very often".
It provides a quick measure of an individual's perceived stress level.
The total score ranges from 0 to 56, corresponding to three stress levels: normal (0-28), elevated (29-42), and high (43-56).
The scale helps identify stress status and provides guidance for adjusting support resources.
|
Baseline, immediately after the intervention, one month after the intervention,
|
|
Change of the sleep quality
기간: Baseline, immediately after the intervention, one month after the intervention,
|
Sleep quality will be measured by the Pittsburgh Sleep Quality Index (PSQI).
The total score of PSQI ranges from 0 to 21, in which higher scores mean poorer sleep quality.
|
Baseline, immediately after the intervention, one month after the intervention,
|
|
Change of the anxiety symptoms
기간: Baseline, immediately after the intervention, one month after the intervention,
|
The GAD-7 is a self-report scale for assessing anxiety symptoms.
It consists of seven items assessing: 1. nervousness or anxiety; 2. uncontrollable worry; 3. excessive worry; 4. difficulty relaxing; 5. restlessness; 6. irritability; and 7. a sense of imp
|
Baseline, immediately after the intervention, one month after the intervention,
|
|
Change of the risky decision-making performance
기간: Baseline, immediately after the intervention
|
Risky decision-making performance will be assessed using the Balloon Analogue Risk Task (BART).
Higher average pumps in the BART indicate greater risk-taking propensity.
Electroencephalography (EEG) will be used to measure neural electrical signals, where increases in relevant electrophysiological indicators may reflect heightened individual sensitivity to negative feedback.
Higher frequency of continued dice rolls indicates greater risk propensity.
Neural activity features related to the task will be analyzed, with specific patterns associated with risk evaluation and reward processing.
|
Baseline, immediately after the intervention
|
|
Changes in Negative Reinforcement Learning Behaviour
기간: Baseline, immediately after the intervention,
|
A negative reinforcement learning paradigm was used to assess avoidance-reversal learning behaviour.
Behavioural response bias and learning rate were used to characterise negative reinforcement behavioural traits and negative reinforcement learning ability.
EEG was recorded simultaneously, and changes in relevant electrophysiological indicators may serve as electrophysiological markers of changes in negative reinforcement learning behaviour.
|
Baseline, immediately after the intervention,
|
|
The change of alcohol craving
기간: Baseline, immediately after the intervention, one month after the intervention,
|
Alcohol craving will be measured by the alcohol craving Visual Analog Scale (VAS).
The total score of VAS ranged from 0 to 10, in which higher scores mean a higher level of alcohol craving.
|
Baseline, immediately after the intervention, one month after the intervention,
|
|
The change of alcohol use
기간: Baseline, immediately after the intervention, one month after the intervention,
|
The AUDIT (the Alcohol Use Disorders Identification Test) consists of 10 items covering drinking frequency, alcohol consumption, alcohol dependence-related symptoms, and adverse consequences caused by alcohol use.
Respondents complete the questionnaire based on their recent drinking behaviour, with each item scored according to different response levels.
The total score ranges from 0 to 40.
Higher scores indicate a higher risk of alcohol-related problems, and the scale can be used to identify hazardous drinking, harmful drinking, and potential risk of alcohol dependence.
|
Baseline, immediately after the intervention, one month after the intervention,
|
|
The changes of Resilience
기간: Baseline, immediately after the intervention, one month after the intervention,
|
The China version of the Connor-Davidson Resilience Scale (CD-RISC) consists of 25 items and includes three dimensions: tenacity (13 items), strength (8 items), and optimism (4 items).
The scale uses a 5-point Likert scoring method, with scores from 0 to 4 representing "not true at all", "rarely true", "sometimes true", "often true", and "true nearly all the time", respectively.
The total score ranges from 0 to 100, with higher scores indicating greater psychological resilience.
The internal consistency coefficient of the Chinese version is 0.91.
|
Baseline, immediately after the intervention, one month after the intervention,
|
|
The condition of childhood experiences
기간: Baseline
|
Adverse Childhood Experiences (ACEs) includes 25 clinical items and 3 validity items.
The scale uses a 5-point scoring system, ranging from "never true" to "very often true".
Each subscale score ranges from 5 to 25 and is calculated by summing the scores of the items within that subscale.
The total CTQ score is calculated by summing the subscale scores.
Higher scores indicate more severe reported childhood maltreatment.
|
Baseline
|
|
The change of nicotine dependence
기간: Baseline, immediately after the intervention, one month after the intervention,
|
The FTND is a self-report scale used to assess the severity of nicotine dependence among smokers.
The scale usually consists of six items.
The total score ranges from 0 to 10, with higher scores indicating more severe nicotine dependence.
It can be used to assess the level of smoking addiction and support the development of smoking cessation interventions.
|
Baseline, immediately after the intervention, one month after the intervention,
|
|
Change of the self-control ability
기간: Baseline, immediately after the intervention, one month after the intervention,
|
Self-control ability will be measured using the Self-Control Scale (SCS).
Higher scores of SCS indicate better self-regulation and impulse control.
|
Baseline, immediately after the intervention, one month after the intervention,
|
|
The changes of impulsive behavior
기간: Baseline, immediately after the intervention, one month after the intervention,
|
UPPS-P Impulsive Behavior Scale (UPPS-P) includes 59 items rated on a 4-point Likert scale.
Respondents indicate their agreement or disagreement with statements using a 4-point scale (1 = Agree Strongly, 4 = Disagree Strongly).
Scoring involves calculating a mean score for each of the five subscales (scaled 1-4) and a total impulsivity score.
|
Baseline, immediately after the intervention, one month after the intervention,
|
|
The changes of morningness-eveningness
기간: Baseline, immediately after the intervention, one month after the intervention,
|
The Chinese version of the 5-item Morningness-Eveningness Questionnaire (rMEQ-5).
The Chinese version of the MEQ-5 consists of five items selected from the Chinese version of the MEQ-19, namely items 1, 7, 10, 18, and 19.
|
Baseline, immediately after the intervention, one month after the intervention,
|
|
The change of impulsiveness
기간: Baseline, immediately after the intervention, one month after the intervention,
|
The Barratt Impulsiveness Scale (BIS) consists of 30 items.
Each item is rated according to the frequency of occurrence using a 4-point scoring method: rarely/never = 1, occasionally = 2, often = 3, and almost always/always = 4.
|
Baseline, immediately after the intervention, one month after the intervention,
|
|
The change of somatic symptom
기간: Baseline, immediately after the intervention, one month after the intervention,
|
The Somatic Symptom Scale (SSS) consists of 20 items and is a self-report scale using a 4-point rating system (Table 1).
A total raw score above 40 is considered positive.
|
Baseline, immediately after the intervention, one month after the intervention,
|
|
The change of behavioral inhibition/activation
기간: Baseline, immediately after the intervention, one month after the intervention,
|
The Behavioral Inhibition/Activation System Scale (BIS/BAS Scale) uses a 4-point scoring system, where 1 indicates "strongly agree" and 4 indicates "strongly disagree".
Higher scores indicate greater activation of the behavioral inhibition system and behavioral activation system.
|
Baseline, immediately after the intervention, one month after the intervention,
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (추정된)
2026년 7월 1일
기본 완료 (추정된)
2027년 12월 1일
연구 완료 (추정된)
2028년 1월 1일
연구 등록 날짜
최초 제출
2026년 7월 1일
QC 기준을 충족하는 최초 제출
2026년 7월 1일
처음 게시됨 (실제)
2026년 7월 8일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2026년 7월 8일
QC 기준을 충족하는 마지막 업데이트 제출
2026년 7월 1일
마지막으로 확인됨
2026년 6월 1일
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .